Anorexia Nervosa Clinical Trial
— ACAMTOOfficial title:
Monocentric Single-blind Randomized Controlled Trial Evaluating the Impact of the Addition of a Specific and Personalized Body Approach by Osteopathic Treatment in the Care of Adolescents With Anorexia Nervosa
Abstract: Background: Anorexia nervosa (AN) is a common pathology affecting mainly women (sex ratio 1/10), which starts most often during adolescence. The prognosis of the AN remains poor (10% of deaths and high risk of chronicity). Body dissatisfaction, disturbances in recognition and identification of body sensations are some of the key symptoms of AN. There is, however, a contrast between this consensual observation of the importance of troubles in body image in AN, and the relative deficit of specifically targeted body treatments. Our proposal for a body approach specifically dedicated to AN is based on the understanding that posture, breathing, muscle tension and body perception are closely linked to our psychological and emotional state, and are therefore disturbed in patients with AN. The purpose of this monocentric randomized controlled trial is to evaluate if a targeted osteopathic protocol treatment for AN in addition to as-usual care is significantly more effective compared to as-usual care. Methods: Seventy-two female patients meeting the inclusion criteria will be randomly assigned to one of the two treatment groups : one receiving the specific osteopathic treatment targeted for AN in addition to the as-usual care (group A) and the other one, the as-usual care (group B). The patients of group A will receive 5 sessions of osteopathic treatment for 25 minutes. Soft specific palpatory techniques on the diaphragm, digestive system and cervical region will be realized. The as-usual care is defined by the multidisciplinary approach recommended by the high authority of health. The primary outcome is the evaluation of interoceptive sensibility and secondary outcomes include clinical and psychopathology-related symptoms and assessment of somatic dysfonctions' evolution. A qualitative study will also be carried out, applying the Interpretative Phenomenological Analysis method. Patients will be included for a maximum of 14 weeks between the inclusion time and the last evaluation. Discussion: If the results of the study are positive (statistically significant effectiveness of this body approach in addition to as-usual care compared to as-usual treatment), patients with anorexia will be benefit from the possibility of additional treatment that is effective, relatively inexpensive, non-invasive and non-pharmacological.
Status | Recruiting |
Enrollment | 72 |
Est. completion date | April 1, 2022 |
Est. primary completion date | April 1, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 13 Years to 20 Years |
Eligibility | Inclusion Criteria: - female - patient aged between 13 to 20 years included - patient has a Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) diagnosis of Nnorexia nervosa (restricting or binge-eating/purging types) - Body Mass Index (BMI) = 14 kg.m-² - Followed up in consultation for at least 2 months or hospitalized in the psychiatry unit of Institut Mutualiste Montsouris - has a clinical/somatic state compatible with the conduct of osteopathic treatment sessions (prior medical advice) - is not in "separation period" (In the adolescent and young adult psychiatry department of Institut Mutualiste Montsouris, during a full-time hospitalization for AN, the "separation period" is linked to the establishment of a hospitalization contract between the medical team, the family and the patient. This contract will define a time of separation between the family and the patient. It is built around two axes: the final discharge weight allowing the patient to leave the service and the intermediate weight called "separation lifting weight". This lifting weight of separation is thus named because it puts an end to the first part of hospitalization that takes place in separation from the living environment of the patient (parents, friends, schooling...) - signed the Informed Consent Form and both parents for minor patient, - is not included in another research protocol. Non-inclusion criteria: - male - patient under 13 years old or over 20 years old - has contraindication to osteopathic body approach sessions (fracture, recent surgery, etc.) - with a Body Mass Index (BMI) < 14 kg.m-² - patient needs a naso-gastric tube - is in "separation period" - is not fluent in French - is not covered by health insurance - is included in another research protocol. Exclusion criteria: - patient has contraindication to osteopathic body approach sessions (fracture, recent surgery, somatic state not compatible with the osteopathic treatment) - is not covered by health insurance - is included in another research protocol. |
Country | Name | City | State |
---|---|---|---|
France | Institut Mutualiste Montsouris | Paris |
Lead Sponsor | Collaborator |
---|---|
Institut Mutualiste Montsouris | Fondation de l'Avenir |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the evolution of interoceptive sensitivity | fMAIA scale : Multidimensional Assessment of Interoceptive Awareness, French version | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Primary | To evaluate the evolution of interoceptive sensitivity | fMAIA scale : Multidimensional Assessment of Interoceptive Awareness, French version | Arm 1: Before the 3rd session of osteopathic treatment, Arm 2: 3 weeks after the first questionnaires | |
Primary | To evaluate the evolution of interoceptive sensitivity | fMAIA scale : Multidimensional Assessment of Interoceptive Awareness, French version | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of weight | Weight measured in kilograms | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the evolution of weight | Weight measured in kilograms | Arm 1: Before the 3rd session of osteopathic treatment, Arm 2: 3 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of weight | Weight measured in kilograms | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the presence of any physical pain | Actual physical pain (yes/no), precision of the localisation and intensity by Visual Analog Score (from 0 to 10) | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the presence of any physical pain | Actual physical pain (yes/no), precision of the localisation and intensity by Visual Analog Score (from 0 to 10) | Arm 1: Before the 3rd session of osteopathic treatment, Arm 2: 3 weeks after the first questionnaires | |
Secondary | To evaluate the presence of any physical pain | Actual physical pain (yes/no), precision of the localisation and intensity by Visual Analog Score (from 0 to 10) | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the presence of constipation | Any constipation (yes/no) and precision of number of bowel movements per week | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the presence of constipation | Any constipation (yes/no) and precision of number of bowel movements per week | Arm 1: Before the 3rd session of osteopathic treatment, Arm 2: 3 weeks after the first questionnaires | |
Secondary | To evaluate the presence of constipation | Any constipation (yes/no) and precision of number of bowel movements per week | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of nature of patient's eating disorder symptoms | EDDS : Eating Disorder Diagnostic Scale. Self-reported questionnaire for diagnosis of eating disorders. | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the evolution of nature of patient's eating disorder symptoms | EDDS : Eating Disorder Diagnostic Scale. Self-reported questionnaire for diagnosis of eating disorders. | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of seriousness of patient's eating disorder symptoms | EDI-2: Eating Disorders Inventory. The EDI-2 total score ranges from 91 to 546. Higher score means a worse outcome. | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the evolution of seriousness of patient's eating disorder symptoms | EDI-2: Eating Disorders Inventory. The EDI-2 total score ranges from 91 to 546. Higher score means a worse outcome. | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of seriousness of concerns about body image | BSQ: Body shape questionnaire. The BSQ score ranges from 34 to 204. Higher score means a worse outcome. | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the evolution of seriousness of concerns about body image | BSQ: Body shape questionnaire. The BSQ score ranges from 34 to 204. Higher score means a worse outcome. | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of seriousness of alexithymia | BVAQ-B: Bermond-Vorst Alexithymia Questionnaire Form B. The BVAQ-B score ranges from 20 to 100. Higher score means a worse outcome. | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the evolution of seriousness of alexithymia | BVAQ-B: Bermond-Vorst Alexithymia Questionnaire Form B. The BVAQ-B score ranges from 20 to 100. Higher score means a worse outcome. | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of seriousness of self-esteem | RSE: Rosenberg Self-esteem Scale. The RSE score ranges from 10 to 40. Higher score means a worse outcome. | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the evolution of seriousness of self-esteem | RSE: Rosenberg Self-esteem Scale. The RSE score ranges from 10 to 40. Higher score means a worse outcome. | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of seriousness of anxiety | STAI-Y: State-Trait Anxiety Inventory, Form Y. The STAI-Y score ranges from 20 to 80. Higher score mean a worse outcome. | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the evolution of seriousness of anxiety | STAI-Y: State-Trait Anxiety Inventory, Form Y. The STAI-Y score ranges from 20 to 80. Higher score mean a worse outcome. | Arm 1: Before the 3rd session of osteopathic treatment, Arm 2: 3 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of seriousness of anxiety | STAI-Y: State-Trait Anxiety Inventory, Form Y. The STAI-Y score ranges from 20 to 80. Higher score means a worse outcome. | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of seriousness of depressive experiences | DEQ: Depressive Experiences Questionnaire - Adolescent Version. The Depressive Experiences Questionnaire (DEQ) is a 66 item questionnaire where participants rate themselves on life experiences and personality characteristics frequently associated with depression. Participants are asked to rate each item on a seven-point Likert-type scale ranging from strongly disagree (1) to strongly agree (7). Analysis of results produces 3 factors: Dependency, Self-criticism, and Efficacy. | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the evolution of seriousness of depressive experiences | DEQ: Depressive Experiences Questionnaire - Adolescent Version. The Depressive Experiences Questionnaire (DEQ) is a 66 item questionnaire where participants rate themselves on life experiences and personality characteristics frequently associated with depression. Participants are asked to rate each item on a seven-point Likert-type scale ranging from strongly disagree (1) to strongly agree (7). Analysis of results produces 3 factors: Dependency, Self-criticism, and Efficacy. | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of seriousness of depression | HAD-depression: Hospital Anxiety and Depression scale-depression. The HAD-depession score ranges from 0 to 21. Higher score means a worse outcome. | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the evolution of seriousness of depression | HAD-depression: Hospital Anxiety and Depression scale-depression. The HAD-depession score ranges from 0 to 21. Higher score means a worse outcome. | Arm 1: Before the 3rd session, Arm 2: 3 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of seriousness of depression | HAD-depression: Hospital Anxiety and Depression scale-depression. The HAD-depession score ranges from 0 to 21. Higher score means a worse outcome. | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of nature and seriousness of self-injury | OSI: Ottawa Self-injury Questionnaire. OSI (Ottawa Self-Injury) to measure occurrence, frequency, level of motivation to stop, types and functions and potential addictive features of self-injury | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the evolution of nature and seriousness of self-injury | OSI: Ottawa Self-injury Questionnaire. OSI (Ottawa Self-Injury) to measure occurrence, frequency, level of motivation to stop, types and functions and potential addictive features of self-injury | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of quality of life | ED-QOL: Eating Disorders Quality of Life Scale. The EDQOL has 25 items that contribute to four subscales (Psychological, Physical/Cognitive, Work/School, and Financial), which combined produce an overall quality of life score. Each item is coded on a five-point scale and asks the participant to rate the extent to which they perceive their eating disorder to affect their quality of life in different domains. Higher scores indicate lower quality of life. | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the evolution of quality of life | ED-QOL: Eating Disorders Quality of Life Scale. The EDQOL has 25 items that contribute to four subscales (Psychological, Physical/Cognitive, Work/School, and Financial), which combined produce an overall quality of life score. Each item is coded on a five-point scale and asks the participant to rate the extent to which they perceive their eating disorder to affect their quality of life in different domains. Higher scores indicate lower quality of life. | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of seriousness of physical activity dependence | EDS-R: Exercise-Dependence Scale-Revised, The EDS-R score ranges from 21 to 126. Higher score means worse outcome | Arm 1: 3 weeks after inclusion ie 1 week before the first session, Arm 2: 3 weeks after inclusion | |
Secondary | To evaluate the evolution of seriousness of physical activity dependence | EDS-R: Exercise-Dependence Scale-Revised, The EDS-R score ranges from 21 to 126. Higher score means worse outcome | Arm 1: Before the 3rd session, Arm 2: 3 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of seriousness of physical activity dependence | EDS-R: Exercise-Dependence Scale-Revised, The EDS-R score ranges from 21 to 126. Higher score means worse outcome | Arm 1: 1 week after the 5th session of osteopathic treatment, Arm 2: 6 weeks after the first questionnaires | |
Secondary | To evaluate the evolution of somatic dysfonctions (for Arm 1) | SOAP note form. This is a standardized tool to evaluate somatic dysfunctions (sensitivity, mobility, texture, asymmetry) and severity (from 0 to 3) for each body region | Arm 1: before each of the 5 osteopathic treatment sessions | |
Secondary | To evaluate the evolution of somatic dysfonctions (for Arm 1) | SOAP note form. This is a standardized tool to evaluate somatic dysfunctions (sensitivity, mobility, texture, asymmetry) and severity (from 0 to 3) for each body region | Arm 1:1 week after the 5th session of osteopathic treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05531604 -
Appetitive Conditioning in Anorexia Nervosa
|
||
Enrolling by invitation |
NCT04174703 -
Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing
|
N/A | |
Active, not recruiting |
NCT04883554 -
Impact of an Olfactory Sensory Therapeutic Group for Adolescent Patients With Restrictive Anorexia Nervosa , Pilot Study
|
N/A | |
Recruiting |
NCT04213820 -
TMS and Body Image Treatment for Anorexia Nervosa
|
N/A | |
Completed |
NCT03414112 -
The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa
|
Early Phase 1 | |
Recruiting |
NCT06144905 -
Norwegian Microbiota Study in Anorexia Nervosa
|
||
Recruiting |
NCT05803707 -
Home-based Adapted Physical Activity in Anorexia Nervosa: a Feasibility Pilot Study
|
N/A | |
Recruiting |
NCT05682417 -
Impact of Body Schema Distortion on Remission and Weight Regain in Anorexia Nervosa
|
N/A | |
Not yet recruiting |
NCT06380257 -
Anorexia Nervosa and Brain in Adolescence
|
||
Not yet recruiting |
NCT04804800 -
Virtual Reality Place in the Management of Body Dysmorphia Disorders in Anorexia Nervosa
|
N/A | |
Not yet recruiting |
NCT03600610 -
Evaluation of CARdiac Abnormalities by Echocardiography and MRI in Malnourished Patients Suffering From Anorexia Nervosa
|
N/A | |
Completed |
NCT02745067 -
Effectiveness of Enhanced Cognitive Behavioral Therapy (CBT-E) in the Treatment of Anorexia Nervosa
|
N/A | |
Completed |
NCT02382055 -
Changing Habits in Anorexia Nervosa: Novel Treatment Development
|
N/A | |
Terminated |
NCT02240797 -
Kappa Opioid Receptor Imaging in Anorexia
|
N/A | |
Completed |
NCT03075371 -
Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa
|
N/A | |
Unknown status |
NCT01761942 -
Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa
|
Phase 2 | |
Completed |
NCT03144986 -
Insula-coil Deep TMS for Treatment Resistant Anorexia Nervosa
|
N/A | |
Completed |
NCT01579682 -
Adaptive Family Treatment for Adolescent Anorexia Nervosa
|
N/A | |
Completed |
NCT02551445 -
A fMRI Pilot Study of the Effects of Meal-support in Eating Disorders.
|
N/A | |
Completed |
NCT00946816 -
The Effects of Dietary Intervention on Gastrointestinal Function in Patients With Anorexia Nervosa and Obesity
|
N/A |